Background: Point-of-care (POC) tests are an important strategy to address the epidemic of sexually transmitted infections (STIs). The leucocyte esterase test (LET) can be used as a POC test for chlamydia. The aim of this study was to determine the diagnostic accuracy of the LET to detect urogenital chlamydia among men at STI clinics in Paramaribo, Suriname and Amsterdam, the Netherlands.
Background
Chlamydia trachomatis (Ct) is the most common cause of nongonoccal urethritis in men [1] . In resource-limited settings management of male urethritis is generally based on a syndromic approach: when a patient has typical symptoms like urethral discharge, penile itching or dysuria, immediate treatment with antibiotics is given. Yet, with a syndromic approach, a significant proportion of men infected with Ct are missed, as the majority of men does not have symptoms [2] . The proportion of cases that are asymptomatic varies by population and ranges from 40 to 96 % [3] [4] [5] . Moreover, a syndromic approach also can lead to overtreatment, antibiotic overconsumption, induction of side effects and antimicrobial resistance of infections like Neisseria gonorrhoeae (Ng). Also, effective contact tracing and treatment is challenging based on a presumptive diagnosis only.
Point of care (POC) management can partly overcome the disadvantages of syndromic management. POC testing is defined as medical testing at or near the site of patient care [6] . Ideally a POC test should meet the AS-SURED criteria of the World Health Organization; Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, Deliverable to those who need them [7] . Recently, several companies have developed commercial POC tests based on bacterial antigens that provide rapid results for the detection of Ct, but the sensitivity of these tests is low (17-65 %) and this precludes more widespread use in clinical settings [6, [8] [9] [10] . The Cepheid GeneXpert Ct/Ng assay is a rapid (<2 h to results) nucleic acid amplification test (NAAT) assay that can be performed in on-site laboratories, but the high costs are an obstacle for implementation in low-and middle-income countries. Moreover it is questionable if patients are willing to wait 2 h for their test result [11] . As long as no other promising POC test is available, sexually transmitted infections (STI) clinics are dependent on convential techniques like light microscopy and dipstick urinalysis with the leucocyte esterase test (LET).
Light microscopy is used in the POC management of various STIs [1] . However, light microscopy requires a laboratory infrastructure that is often lacking in resourcelimited settings. In these settings the LET might be an alternative for light microscopy, because it is cheap, easy to perform and does not require a laboratory [12, 13] . LET is available as dipstick assay and is used to detect a urinary inflammatory reaction through the presence of an esterase enzyme produced by polymorph nuclear leucocytes (PMNL) in the urine, possibly associated with either a urinary tract infection or STI in males [14] .
Suriname is a middle-income country in South America with most of the population concentrated in the coastal region, and the remainder in sparsely populated, predominantly remote areas. For these settings, an equipmentfree POC test could be of great benefit. The Netherlands is a high-income country in Europe, but also there an equipment-free POC test may be useful in certain primary health care settings like general practitioners clinics.
Previous studies that investigated the performance of the LET to detect urogenital Ct in males have reported sensitivities and specificities ranging from 46 to 100 % and 60 to 96 % respectively [15] [16] [17] [18] [19] . The variety of outcomes can be explained by a difference in settings, patient groups, experimental test thresholds and reference tests. In most of the studies obsolete reference tests like ligase chain reaction (LCR) were used and/or investigated the LET in either symptomatic or asymptomatic patients in one setting [16, [20] [21] [22] [23] [24] [25] [26] [27] [28] .
The aim of our study was to evaluate the diagnostic performance of the LET as a POC test for urogenital Ct compared to NAAT in male patients irrespective of symptoms attending STI outpatient clinics in two different settings; an outpatient clinic in a middle-income country, Suriname, and in a high-income country, the Netherlands.
Methods

Study design, selection of patients
Participants were recruited at: In both countries demographic characteristics and data regarding symptoms were obtained using a questionnaire. Patients were regarded as symptomatic when either dysuria, urethral discharge or scrotal pain was reported in the questionnaire.
Leucocyte esterase test (LET)
The LET (Combur 2 Test LN, Roche Diagnostics, GmbH, Mannheim, Germany) is a non-specific rapid dipstick assay used to detect the presence of an esterase enzyme produced by PMNL's in urine. The presence of PMNL's in urine indicates an inflammatory response, possibly caused by an infection. In Suriname and the Netherlands patients provided urine samples that were immediately brought to the on-site laboratory by nurses. A laboratory technician performed the LET within two hours of sample collection and placed the dipstick in a urine sample according to the manufacturer's instructions. The results were read after 2 and 5 min. Using a reference color table, the dipstick differentiated between negative, 1+ (ca. 10-25 PMNL/μl), 2+ (ca. 75 PMNL/μl), 3+ (ca. 500 PMNL/ μl). The LET was regarded positive when the dipstick colored ≥ 1+. Patients with a failed or missing LET were excluded from the analyses.
Reference tests
The Aptima Ct assay (Hologic Gen-Probe, USA) was used as the reference NAAT to detect urogenital Ct both in the Netherlands and Suriname. Reference testing was performed on the same urine sample that was used for the LET. In the Netherlands the samples were tested the same week at the Public Health Laboratory in Amsterdam. In Suriname, the samples were collected according to the manufacturer's (Hologic) instructions, stored in a fridge (at temperature between 2°a nd 7°C) and packed according to international air transport association (IATA) rules for transport by plane to the Public Health Laboratory in Amsterdam for NAAT testing. According to the manufacturer's instructions the samples had to be analysed within 30 days after collection. In our study 349 of the 412 samples (84.7 %) were analysed within 30 days and 63 samples (15.3 %) were tested between 31 and 48 days (median time: 35 days (IQR 33-36 days)). More details about the data collection were previously described [8, 30] .
Diagnostic performance and statistical analysis
The diagnostic performance of the LET was investigated by calculating the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), the percentage agreement and kappa. A kappa value >0.61 was considered as good test agreement, κ = 0.41-0.60 as fair agreement, κ = 0.21-0.40 as slight agreement, κ = 0.01-0.20 as poor agreement, and κ ≤ 0.00 as no agreement) [31] .
As prescribed by the manufacturer the LET was read 2 min after it was placed in urine (from here onwards described as "LET 2 m"). We also read the result of the LET 5 min after it was placed in urine (from now on described as "LET 5 m") to evaluate the influence of timing on the diagnostic performance.
We compared the diagnostic performance of the LET 2 m between symptomatic and asymptomatic patients and conducted a subgroup analysis for individuals <25 years.
Characteristics of the study populations were compared using the Pearson's chi-square test. When the expected cell-count was <5 the Fisher's exact test was used. We considered a p-value <0.05 as statistically significant. Analyses were performed with SPSS package version 21 (SPSS Inc., Chicago, Illinois, USA) and STATA software V11.2 (Stata Corp, College Station, Texas, USA).
Results
Study populations Suriname
In total 415 patients provided samples for the study, of which three patients had an invalid LET result and were excluded. From the remaining 412 patients 279 (67.7 %) of the patients were symptomatic and 133 (32.3 %) were asymptomatic. The median age was 28 years (interquartile range (IQR) 24.0-37.0). Ct prevalence was 22.8 % (95 % CI 19.0-27.1) ( Table 1 ).
The Netherlands
In total 647 patients provided samples for the study of which two patients had an invalid LET result and were excluded. Data regarding symptoms were missing for nine patients. Among the remaining 636 patients 257 (40.4 %) of the patients were symptomatic and 379 (59.6 %) were asymptomatic. The median age was 34 years (IQR 26.5-43.0). Ct prevalence was 13.6 % (95 % CI 11.2-16.5). (Table 3 ). The sensitivity of the LET 5 m was 90.9 %; significantly higher than the sensitivity of the LET 2 m (p = 0.013). The specificity of the LET 5 m was 40.8 %; significantly lower than the specificity of the LET 2 m (p < 0.001).
The sensitivity of the LET 2 m was not significantly different between symptomatic and asymptomatic patients (p = 0.096), but the specificity was significantly lower among symptomatic patients (51.0 %) than among asymptomatic patients (62.6 %) (p = 0.008). In the younger age group (<25 years) a high prevalence of Ct was found (19.1 %) but the sensitivity and specificity of the LET 2 m in this group were not significantly different compared with the age group ≥ 25 years (p = 0.290 and p = 0.377).
Compared with Suriname the sensitivity of the LET 2 m was significantly lower; 77.3 % versus 92.6 % (p = 0.004).
Discussion
To our knowledge this is the first multi-center study that evaluated the LET to detect urogenital Ct among men in clinics in both a middle-income country and in a highincome country with high Ct prevalences (22.8 % and 13.6 %, respectively).
Both in Suriname and the Netherlands the LET 2 m had a reasonably high sensitivity (respectively 92.6 and 77.3 %) but a poor specificity (respectively 38.1 and 58.1 %) and a poor agreement (respectively kappa 0.179 and 0.176). The significantly higher sensitivity of the LET 2 m we found in Suriname compared with the Netherlands can be caused by a difference in study populations. In the Netherlands significantly more patients were asymptomatic (59.6 %) compared with Suriname (32.3 %). Wiggins et al. suggested that asymptomatic patients have infections with a lower infection-load and therefore fewer leucocytes which might cause false negative test results [32] . The same group showed that the number of leucocytes (predominantly PMNL's) was strongly correlated with urethritis and proved that men with asymptomatic urethritis have fewer PMNL's than symptomatic men [33] . A Swedish study conducted among 480 male patients of an STI clinic (also with Ct as outcome and ≥1+ as cutoff point) supports this hypothesis: the LET had a significantly higher sensitivity (69.6 % versus 25.9 %) but a lower specificity (76.3 % versus 85.8 %) among symptomatic patients compared with asymptomatic patients [17] .
Moreover, in both countries the LET 2 m showed a significantly higher specificity in asymptomatic patients compared with symptomatic patients. A possible explanation can be that symptomatic patients had relatively more often infections like Neisseria gonorrhoeae (Ng), Mycoplasma genitalum (Mg) or Trichomonas Vaginalis (Tv) compared to asymptomatic patients which could have caused a relative higher proportion of 'false positive' results [34] [35] [36] . Also in a previous study we showed that light microscopic examination of Gram stained urethral smears is less specific to detect urogenital Ct infections when done in samples of symptomatic males only [37] .
In the Netherlands the sensitivity of the LET increased and in both countries the specificity decreased when the incubation time was prolonged from 2 to 5 min. A study of Morré et al. found also a higher sensitivity when the reading time was prolonged from 2 to 5 min [38] .
The strength of our study is that we explored the diagnostic accuracy of the LET among both symptomatic and asymptomatic male patients in a high-and in a middle-income country with a different Ct prevalence. A shortcoming is that we only focused on Ct and not on other causative micro-organisms of urethritis like Ng, Mg or Tv. Evaluation of other micro-organisms could have [8] .
Syndromic management based on symptoms falls short and leaves many asymptomatic infections untreated [40, 43] . As long as no accurate and affordable POC tests for Ct are available, the LET could be a cheap and an easy to perform alternative to exclude urogenital Ct infections among men in settings where any Ct diagnostics are lacking. The sensitivity we found for the LET in Suriname (91.6 %) was reasonably high. It is estimated that a POC test of even moderate sensitivity (63 %) combined with immediate treatment on-site may lead to the treatment of more infected individuals than an ultra-sensitive and specific NAAT alone when patient return is low [44] .
Settings lacking any STI laboratory diagnostics now mainly rely on syndromic management for STI treatment. Further studies into the diagnostic performance of the LET test as opposed to routine syndromic management are needed; the effect on overtreatment due to low specificity would be an important end point.
Our previous study on the cost-effectiveness of microscopic examination of Gram stained urethral smears compared to NAAT at the STI outpatient clinic in Amsterdam showed a sensitivity of 83.8 % and specificity of 74.1 %, comparable with the sensitivity and specificity of the LET we found in the current study [37] . However, if available, microscopy is preferable above the LET because it can also detect Ng infections by finding Gram negative diplococci in a Gram stained smear.
Conclusion
In conclusion, we showed that the LET has a reasonably high sensitivity but a low specificity to diagnose urogenital Ct in male STI clinic visitors. Future studies that also include the detection of other main causative infections of urethritis are needed to compare the cost-effectiveness of the LET in comparison with syndromic management. 
